Insulin detemir in the management of type 2 diabetes in non-Western countries: Safety and effectiveness data from the A1chieve observational study
Diabetes Research and Clinical Practice, 3, 101, pages 317 - 325
Received 24 December 2012, Revised 16 May 2013, Accepted 6 June 2013, Published online Oct-2013
Conflicts of interest
All authors were members of the A1chieve study advisory board and received support from Novo Nordisk to attend advisory board meetings. Prof. Shah has no other conflicts of interest to declare. Dr Zilov is an opinion leader and lecturer for Novo Nordisk, Sanofi-Aventis, Novartis, MSD, Merck & Co, Berlin-Chemi, and Abbott. Dr El Naggar has received speaker fees from Pfizer, MSD, Novartis, Novo Nordisk, AstraZeneca, Sanofi-Aventis, and Merck Serono, and has participated in advisory boards for Eli Lilly, Bristol-Myers Squibb, and SanofiAventis. Chunduo Shen is employed by Novo Nordisk. Dr Haddad has acted as a consultant for Sanofi-Aventis, Eli Lilly, Takeda, MSD, Bristol-Myers Squibb, and GlaxoSmithKline, for which he received honoraria.
© 2013 Published by Elsevier B.V.